Last $9.00 USD
Change Today -0.31 / -3.33%
Volume 47.1K
XNCR On Other Exchanges
Symbol
Exchange
NASDAQ GM
Munich
As of 8:10 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

xencor inc (XNCR) Snapshot

Open
$9.33
Previous Close
$9.31
Day High
$9.33
Day Low
$9.00
52 Week High
03/14/14 - $14.41
52 Week Low
12/3/13 - $5.75
Market Cap
282.6M
Average Volume 10 Days
48.9K
EPS TTM
--
Shares Outstanding
31.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENCOR INC (XNCR)

Related News

No related news articles were found.

xencor inc (XNCR) Related Businessweek News

No Related Businessweek News Found

xencor inc (XNCR) Details

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through its proprietary XmAb technology platform. The company’s lead XmAb-engineered antibodies include XmAb5871, a B-cell inhibitor, which is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor under Phase Ib clinical trial initiation to treat asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate that is in Phase II clinical trials for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.

28 Employees
Last Reported Date: 03/31/14
Founded in 1997

xencor inc (XNCR) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $363.7K
Chief Medical Officer
Total Annual Compensation: $322.5K
Chief Business Officer
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2013.

xencor inc (XNCR) Key Developments

Xencor, Inc. Announces Executive Appointments

Xencor, Inc. announced the appointment of Debra Zack, M.D., Ph.D., vice president, clinical development and the appointment of Lloyd Rowland, senior vice president, chief compliance officer and general counsel. Dr. Zack joins Xencor with more than a decade of experience in drug development. Prior to joining Xencor, Dr. Zack was executive director, medical scientific leader at Novartis Institute for Biological Research. Before that, she had a long career at Amgen in various pre-clinical, clinical development, and medical affairs roles, most recently as the executive director, global development lead for Enbrel and executive director, global product area lead for rheumatology and dermatology.

Xencor, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Xencor, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, revenues were $0.8 million against $3.9 million last year. Loss from operations was $5.1 million against $1.0 million last year. Net loss attributable to common stockholders was $5.0 million or $0.16 per basic and diluted share against net income attributable to common stockholders of $97.0 million or $3.88 per diluted share last year. For the six months, revenues were $3.0 million against $5.3 million last year. Loss from operations was $8.8 million against $5 million last year. Net loss attributable to common stockholders was $8.8 million or $0.28 per basic and diluted share against net income attributable to common stockholders of $92.4 million or loss of $4.35 per diluted share last year. The reduction in revenue for the three and six months ended June 30, 2014 compared to the same periods in 2013 relates primarily to the $3.0 million in milestone revenue received under the company's Morphosys collaboration in the second quarter of 2013. Revenues are earned from technology licensing fees and milestone payments from Xencor's partners for the license of its drug candidates and use of its proprietary XmAb antibody engineering technologies. The lower loss on a per share basis in the three and six month periods ended June 30, 2014 compared to the same periods in 2013 are primarily due to a non-cash expense of $48.6 million related to the loss on the settlement of convertible notes that is reflected in the 2013 losses and the additional shares reflected in the 2014 per share calculations as a result of the company's IPO in December 2013.

Xencor, Inc. to Report Q2, 2014 Results on Jul 31, 2014

Xencor, Inc. announced that they will report Q2, 2014 results After-Market on Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNCR:US $9.00 USD -0.31

XNCR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XNCR.
View Industry Companies
 

Industry Analysis

XNCR

Industry Average

Valuation XNCR Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENCOR INC, please visit www.xencor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.